Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if bupropion will improve the symptoms of restless legs syndrome (RLS).
Adult patients with moderate to severe RLS will be recruited for the study. Those on medications which treat RLS will be asked to discontinue the medications for two weeks prior to beginning the study. All participants will be screened with Beck Depression Inventory, International Restless Legs Syndrome Study Group (IRLSSG) severity scale, and Clinical Global Impression of Improvement (CGI-I) scale. An ordinal scale (i.e. rate symptoms from 1-8) will also be obtained. Participants will be randomized to a placebo or medication group. Those in the medication group will be given 150 mg of bupropion at night for six weeks. Others will receive similar-appearing placebo. Participants will be called at the end of weeks one, two, four and five to assess symptom severity based on IRLSSG scale, and to determine if they are experiencing any adverse effects. At three weeks and six weeks, participants will return to the clinic to complete all four of the initial forms, the Beck Depression Inventory, IRLSSG severity scale, ordinal scale, and CGI-I.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Participants will receive 150MG Bupropion nightly. |
|
| 2 | Placebo Comparator | Participants will receive matching placebo capsule nightly. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bupropion | Drug | Partipants will receive 150 mg bupropion per night |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in International Restless Legs Syndrome Study Group (IRLSSG) Severity Scale. | Scale ranges from 0 to 40 points with higher scores being associated with more severe symptoms of restless legs syndrome. There are 10 questions, with points of 0 to 4 per question. The change in IRLSSG score from baseline is recorded at three and six weeks. | Baseline, three weeks, and six weeks |
| Clinical Global Impression - Improvement Scale | three weeks and six weeks | |
| Ordinal Scale (i.e., 1-8) of Symptom Severity | three weeks and six weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| East Tennessee State University | Johnson City | Tennessee | 37614 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Bupropion | Participants will receive 150MG Bupropion nightly. |
| FG001 | Placebo | Participants will receive matching placebo capsule nightly. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Bupropion | Participants will receive 150MG Bupropion nightly. |
| BG001 | Placebo | Participants will receive matching placebo capsule nightly. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in International Restless Legs Syndrome Study Group (IRLSSG) Severity Scale. | Scale ranges from 0 to 40 points with higher scores being associated with more severe symptoms of restless legs syndrome. There are 10 questions, with points of 0 to 4 per question. The change in IRLSSG score from baseline is recorded at three and six weeks. | Intention to Treat | Posted | Mean | Standard Deviation | points on a scale | Baseline, three weeks, and six weeks |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Bupropion | Participants will receive 150MG Bupropion nightly. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| miscarriage | Pregnancy, puerperium and perinatal conditions | Pregnancy was an exclusion criterion; participant denied pregnancy initially. Following this event, criteria to avoid possibility of similar event were added. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| nausea | Gastrointestinal disorders |
Possible Type II error as we were unable to recruit our target of 100 participants.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Max Bayard MD | East Tennessee State University | 802-524-8805 | mmbayard3@gmail.com |
Not provided
| ID | Term |
|---|---|
| D012148 | Restless Legs Syndrome |
| ID | Term |
|---|---|
| D009422 | Nervous System Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D016642 | Bupropion |
| ID | Term |
|---|---|
| D011427 | Propiophenones |
| D007659 | Ketones |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | 1 capsule nightly for six weeks |
|
| Adverse Event |
|
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
|
| Primary | Clinical Global Impression - Improvement Scale | Once we started recruiting patients, we had decided not to do this outcome so this data was not obtained. | Posted | three weeks and six weeks |
|
|
| Primary | Ordinal Scale (i.e., 1-8) of Symptom Severity | Once we started recruiting patients, we had decided not to do this outcome so this data was not obtained. | Posted | three weeks and six weeks |
|
|
| 1 |
| 29 |
| 1 |
| 29 |
| EG001 | Placebo | Participants will receive matching placebo capsule nightly. | 0 | 31 | 2 | 31 |
|
Not provided
Not provided
| D020447 |
| Parasomnias |
| D001523 | Mental Disorders |